Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840439 | 0.74 | CYP1A2 (0.36) | PDPK1ALDH1A1PARP1CCR8CYP1A2 | |
| SCHEMBL220723 | 0.67 | — | — | |
| SCHEMBL1457910 | 0.67 | PDPK1 (0.52) | PDPK1ALDH1A1DAOPARP1HTR2A | |
| SCHEMBL5039480 | 0.67 | — | — | |
| SCHEMBL3842031 | 0.66 | CYP1A2 (0.36) | ALDH1A1PARP1CCR8KMT2AHSD17B10 | |
| SCHEMBL2156749 | 0.65 | — | — | |
| SCHEMBL169946 | 0.65 | CCR8 (0.46) | ALDH1A1DAOPARP1CCR8HTR2A | |
| SCHEMBL16152549 | 0.65 | — | — | |
| SCHEMBL390375 | 0.65 | PARP1 (0.46) | PDPK1DAOPARP1 | |
| Hydrochloric Acid SCHEMBL391441 | 0.64 | PARP1 (0.44) | PDPK1DAOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259115-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Crestone, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| WO-2022125691-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-1730145-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095401-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20240000756-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4259115-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | Crestone, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2022125691-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CRESTONE, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-1028964-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024440-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| CN-1019491-B | PREPAPARATION OF THIOPHENE-PYRIDONE USED AS NEW THERAPEUTIC AGENTS | BOOTS CO PLC (GB) | 1992-12-16 | — | — | CN | disclosed |
| EP-0223420-B1 | CONDENSED IMIDAZOPYRIDINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| US-4753951-A | ANTIDEPRESSANTS, ANXIOLYTICS | SHIONOGI & CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0223420-A1 | Condensed imidazopyridine derivatives | SHIONOGI & CO., LTD. (JP) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PDPK1 12/4885ALDH1A1 2379/4885DAO 3603/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | PDPK1 1637/4885ALDH1A1 3714/4885DAO 1333/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | PDPK1 1637/4885ALDH1A1 3714/4885DAO 1333/4885 |
| US-20240000756-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | MTR, GARS1, AANAT | PDPK1 4448/4885ALDH1A1 1171/4885DAO 43/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | PDPK1 12/4885ALDH1A1 2379/4885DAO 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.